Drugs Made In America Acquisition Corp Rights
DMAAR
35 hedge funds and large institutions have $887K invested in Drugs Made In America Acquisition Corp Rights in 2026 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
9% more funds holding
Funds holding: 32 → 35 (+3)
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
71% less capital invested
Capital invested by funds: $3.07M → $887K (-$2.18M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Meteora Capital
Boca Raton,
Florida
|
+$19.1K |
| 2 |
QL
Quarry LP
New York
|
+$15.8K |
| 3 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$13.8K |
| 4 |
BFM
Boothbay Fund Management
New York
|
+$13.3K |
| 5 |
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System
Harrisburg,
Pennsylvania
|
+$12.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCI
Harraden Circle Investments
New York
|
-$281K |
| 2 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
-$65.4K |
| 3 |
HCM
Heights Capital Management
San Francisco,
California
|
-$37K |
| 4 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$33.1K |
| 5 |
GCL
Glazer Capital LLC
New York
|
-$25.4K |
DMAAR Hedge Fund Activity: Q1 2026 in Review
35 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Drugs Made In America Acquisition Corp Rights (DMAAR) for Q1 2026, worth a combined $887K — down 71% from $3.07M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new DMAAR positions and 3 closed out — a net gain of 3 holders — while 6 added to existing stakes and 10 trimmed.
The largest buyer was Meteora Capital, adding an estimated $19.1K. The largest seller was Harraden Circle Investments, exiting entirely with an estimated $281K sold.
- 35 institutional investors held Drugs Made In America Acquisition Corp Rights (DMAAR) as of Q1 2026, up from 32 in Q4 2025.
- Funds reported $887K of Drugs Made In America Acquisition Corp Rights stock for Q1 2026, down 71% quarter-over-quarter.
- 6 funds opened new Drugs Made In America Acquisition Corp Rights positions in Q1 2026 and 3 closed out, a net change of +3 holders.
- The largest Drugs Made In America Acquisition Corp Rights buyer in Q1 2026 was Meteora Capital, an estimated $19.1K added.
- The largest Drugs Made In America Acquisition Corp Rights seller in Q1 2026 was Harraden Circle Investments, an estimated $281K sold.
Based on aggregated 13F filings for Q1 2026.